Prostate Cancer News and Research

Latest Prostate Cancer News and Research

VHIO, MGHCC sign tumor biomarker agreement

The President of the BBVA Foundation, Francisco Gonz-lez, Jose Baselga, Chief of Hematology/Oncology at Massachusetts General Hospital Cancer Center (MGHCC), and Andr-s de Kelety, Managing Director at the Vall d'Hebr-n Institute of Oncology (VHIO) in Barcelona, yesterday signed the agreement creating the BBVA Foundation Tumor Biomarkers Research Program.

17 Nov 2011

Aurora kinase inhibitor may treat neuroendocrine prostate cancer

An international team of researchers led by clinicians at Weill Cornell Medical College have discovered a genetic Achilles' heel in an aggressive type of prostate cancer -- a vulnerability they say can be attacked by a targeted drug that is already in clinical trials to treat other types of cancers.

17 Nov 2011

New treatment may be on the horizon for neuroendocrine prostate cancers

A recent report in Cancer Discovery, a journal of the American Association for Cancer Research, suggests that a new treatment may be on the horizon for neuroendocrine prostate cancers, the most lethal subtype of this disease.

17 Nov 2011

MDxHealth total revenues decrease 7% for third quarter 2011

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, today issued its business update for the third quarter and for the nine months ended September 30, 2011.

17 Nov 2011

Multivitamin use linked to less healthy behaviors

The lack of evidence on multivitamin health benefits is no impediment to their widespread popularity, with over half the U.S. population popping such pills. This translates into a $27 billion industry, which lures consumers with the illusory promise of better health. But shocking new research suggests taking multivitamins might have the opposite effect -- not simply on the metabolic level, but on a metaphysical one: promoting a false sense of invulnerability that actually leads users to engage in riskier behaviors.

17 Nov 2011

New 2-DG-ABT combination cancer therapy triggers apoptosis

Researchers at the University of California, San Diego School of Medicine and Kyushu University Medical School say a novel combination of a specific sugar molecule with a pair of cell-killing drugs prompts a wide variety of cancer cell types to kill themselves, a process called apoptosis or programmed cell death.

17 Nov 2011

SHARPIN protein regulates human cell activity

The research teams headed by Prof. Johanna Ivaska (University of Turku and VTT Technical Research Centre of Finland) and Prof. Marko Salmi (University of Turku and the National Institute for Health and Welfare) have discovered that the SHARPIN protein regulates human cell activity.

17 Nov 2011

ZIOPHARM announces new preclinical data from two darinaparsin studies on solid tumors

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today new preclinical data from two separate studies of darinaparsin, a novel organic arsenic, in various solid tumor models at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 12-16 in San Francisco.

16 Nov 2011

Amgen's XGEVA delays onset of bone metastases in men with prostate cancer

Amgen announced today the publication of results from a Phase 3 trial (the '147 study) that evaluated XGEVA (denosumab) for use in preventing or delaying the onset of bone metastases in men with nonmetastatic castration-resistant prostate cancer.

16 Nov 2011

Positive data from MDxHealth's prostate cancer test study

MDxHealth SA, a leading molecular diagnostics company in the field of personalized cancer treatment, today announced data showing that a prototype of its Prostate ConfirmMDx test can help urologists distinguish patients who have a true negative biopsy from those who may have occult cancer undetected by prostate biopsy and histopathological review.

15 Nov 2011

Soligenix third quarter revenues increase to $5,796,000

Soligenix, Inc., a development stage biopharmaceutical company, announced today its financial results for the third quarter of 2011.

14 Nov 2011

ZIOPHARM announces darinaparsin preclinical data on prostate cancer

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that results from preclinical studies of darinaparsin (Zinapar or ZIO-101), a novel organic arsenic, in prostate cancer were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 12-16 in San Francisco.

14 Nov 2011

Exelixis reports cabozantinib phase 2 trial data on bone metastases

Exelixis, Inc. today reported interim data on pain relief and related reduction in narcotic analgesic use with cabozantinib in castration-resistant prostate cancer (CRPC) patients with bone metastases.

14 Nov 2011

Regulated gene transcription more complex than previously thought

Cells develop and thrive by turning genes on and off as needed in a precise pattern, a process known as regulated gene transcription. In a paper published in the Nov. 9 issue of the Journal of Neuroscience, researchers at the University of California, San Diego School of Medicine say this process is even more complex than previously thought, with regulated genes actually relocated to other, more conducive places in the cell nucleus.

11 Nov 2011

Drug effectively combats obesity in “couch potato” monkeys” Study

According a new study an experimental anti-cancer drug could help fight obesity. The drug chokes off the blood supply to fat cells and helped obese monkeys slim down in the experiments.

10 Nov 2011

Experimental drug selectively destroys blood supply of fat tissue and decreases body fat

Obese rhesus monkeys lost on average 11 percent of their body weight after four weeks of treatment with an experimental drug that selectively destroys the blood supply of fat tissue, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports in Science Translational Medicine.

10 Nov 2011

JMC launches comprehensive lung cancer program

Recruiting one of the nation's leading specialists in minimally-invasive lung and chest surgery, Jupiter Medical Center (JMC) has launched the first comprehensive program in Palm Beach and Martin counties dedicated to prevention, early detection, treatment and care of patients with lung cancer and other diseases of the chest and lung.

10 Nov 2011

Johns Hopkins researchers unravel how breast cancer metastasizes

The spread of breast cancer is responsible for more than 90 percent of breast cancer deaths. Now, the process by which it spreads—or metastasizes—has been unraveled by researchers at Johns Hopkins. Reporting in two papers, the researchers have discovered the switch that enables breast cancer cells to travel to and be received in the lungs.

9 Nov 2011

Viewpoints: Today's 'personhood' vote in Miss.; reactions to Romney's health care plan

What about in vitro fertilization, a process that both creates and discards embryos? What new rights would be afforded to a fetus, and how would those rights affect or compete with the rights of the woman who carries it? Would a woman who has an abortion be guilty of murder and subject to capital punishment? ... In their quest to ban abortion in Mississippi, the amendment's drafters appear to have rushed past such concerns.

9 Nov 2011

CytRx reports net loss of $0.6 million for third quarter 2011

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the three months and nine months ended September 30, 2011, and provided a business update.

9 Nov 2011